Synopsis
Synopsis
0
VMF
0
FDF
0
Weekly News Recap #Phispers


1. Mls001401438
2. Chembl1895091
3. Hms2051p14
4. Hms2233m10
5. Ccg-101038
6. Nc00288
7. Smr000471620
| Molecular Weight | 478.5 g/mol |
|---|---|
| Molecular Formula | C23H30N2O9 |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 10 |
| Exact Mass | 478.19513054 g/mol |
| Monoisotopic Mass | 478.19513054 g/mol |
| Topological Polar Surface Area | 166 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 507 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Lunsekimig is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.
Lead Product(s): Lunsekimig,Fluticasone Propionate,Salmeterol Xinafoate,Budesonide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 06, 2024
Lead Product(s) : Lunsekimig,Fluticasone Propionate,Salmeterol Xinafoate,Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Details : Lunsekimig is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 06, 2024
Details:
Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.
Lead Product(s): Dupilumab,Fluticasone Propionate,Salmeterol Xinafoate,Budesonide,Formoterol Fumarate,Mometasone Furoate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Regeneron Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 09, 2015
Lead Product(s) : Dupilumab,Fluticasone Propionate,Salmeterol Xinafoate,Budesonide,Formoterol Fumarate,Mometasone Furoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma
Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 09, 2015
Details:
Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.
Lead Product(s): Dupilumab,Mometasone Furoate,Formoterol Fumarate,Salbutamol Sulphate,Levalbuterol Sulfate,Levalbuterol Hydrochloride
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Regeneron Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 15, 2013
Lead Product(s) : Dupilumab,Mometasone Furoate,Formoterol Fumarate,Salbutamol Sulphate,Levalbuterol Sulfate,Levalbuterol Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 15, 2013
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Budesonide is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Lead Product(s): Budesonide,Formoterol Fumarate,Carbon
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 08, 2017
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Budesonide,Formoterol Fumarate,Carbon
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Budesonide is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
March 08, 2017
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Budesonide is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Asthma.
Lead Product(s): Budesonide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 04, 2014
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Budesonide is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
December 04, 2014
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Budesonide is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Lead Product(s): Budesonide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 17, 2012
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers
Details : Budesonide is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 17, 2012
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Budesonide is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Lead Product(s): Budesonide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 25, 2012
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte
Details : Budesonide is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
June 25, 2012
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Charcoal is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Lead Product(s): Carbon,Budesonide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 08, 2012
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Carbon,Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Charcoal is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 08, 2012
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Budesonide is a Steroid drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Lead Product(s): Budesonide,Formoterol Fumarate
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 24, 2011
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic Pilot Study on Budesonide/Formoterol
Details : Budesonide is a Steroid drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
October 24, 2011
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Budesonide is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Lead Product(s): Budesonide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 25, 2011
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Pharmacokinetic Study (BF-BLOCK)
Details : Budesonide is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 25, 2011
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alpha-bromo-4-benzoloxy-3- nitroacetophenone
CAS Number : 43229-01-2
End Use API : Formoterol Fumarate
About The Company : Vamsi Labs, established in 1991, is a leading Indian API manufacturer. Specializing in anti-asthmatic, anti-migraine & anti-psychotic APIs, it caters to domesti...
(4-Methoxy phenyl)-iso propyl benzyl amine hydroch...
CAS Number : 1049695-95-5
End Use API : Formoterol Fumarate
About The Company : Vamsi Labs, established in 1991, is a leading Indian API manufacturer. Specializing in anti-asthmatic, anti-migraine & anti-psychotic APIs, it caters to domesti...
CAS Number : 43229-70-5
End Use API : Formoterol Fumarate
About The Company : Vamsi Labs, established in 1991, is a leading Indian API manufacturer. Specializing in anti-asthmatic, anti-migraine & anti-psychotic APIs, it caters to domesti...
N-(2-hydroxy-5-((RS)-1-hydroxy-2-(((RS)-1-(4-metho...
CAS Number : 73573-87-2
End Use API : Formoterol Fumarate
About The Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services co...
CAS Number : 101-98-4
End Use API : Formoterol Fumarate
About The Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our cor...
4-Benzyloxy-3-Nitro-Alpha-[N-benzyl-N-[1-methyl-2-...
CAS Number :
End Use API : Formoterol Fumarate
About The Company : Gangwal is a progressive and innovative business group with a clear vision and ascertaining new challenges, having a strong foundation supported by strong pilla...

N-O-Dibenzyl Formoterol
CAS Number :
End Use API : Formoterol Fumarate
About The Company : Gangwal is a progressive and innovative business group with a clear vision and ascertaining new challenges, having a strong foundation supported by strong pilla...

2-Bromo-4'-Benzyloxy-3'-nitroacetophenone
CAS Number : 43229-01-2
End Use API : Formoterol Fumarate
About The Company : Hiray Pharma Solutions is an international end-to-end CDMO, facilitating the development and manufacturing of important drug products and key intermediates arou...

4-Hydroxy-3"-nitroacetophenone
CAS Number : 6322-56-1
End Use API : Formoterol Fumarate
About The Company : Progress is a company led by professionals, established by technocrats with a vision for global business expansion. Our headquarters are located in Vashi, Mumba...

2-Bromo-4’-Benzyloxy-3’-Nitro Acetophenone
CAS Number : 43229-01-2
End Use API : Formoterol Fumarate
About The Company : SLN Pharmachem was setup in 1997 with an objective to provide technology based products (Intermediates) for Pharmaceutical, Cosmetic and Fine Chemical Industry....

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AN
Brand Name : FORMOTEROL FUMARATE
Dosage Form : SOLUTION;INHALATION
Dosage Strength : 0.02MG/2ML
Approval Date : 2025-01-30
Application Number : 215907
RX/OTC/DISCN : RX
RLD : No
TE Code : AN
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
RLD : No
TE Code : AN
Brand Name : FORMOTEROL FUMARATE
Dosage Form : SOLUTION;INHALATION
Dosage Strength : 0.02MG/2ML
Approval Date : 2023-03-22
Application Number : 215883
RX/OTC/DISCN : RX
RLD : No
TE Code : AN
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
FORMOTEROL FUMARATE; GLYCOPYRROLATE
Brand Name : BEVESPI AEROSPHERE
Dosage Form : AEROSOL, METERED;INHALATION
Dosage Strength : 0.0048MG/INH;0.0090MG/INH
Approval Date : 2016-04-25
Application Number : 208294
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE
Brand Name : BREZTRI AEROSPHERE
Dosage Form : AEROSOL, METERED;INHALATION
Dosage Strength : 0.16MG/INH;0.0048MG/INH;0.009MG/INH
Approval Date : 2020-07-23
Application Number : 212122
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE
Brand Name : DUAKLIR PRESSAIR
Dosage Form : POWDER, METERED;INHALATION
Dosage Strength : 0.4MG/INH;0.012MG/INH
Approval Date : 2019-03-29
Application Number : 210595
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AN
Brand Name : FORMOTEROL FUMARATE
Dosage Form : SOLUTION;INHALATION
Dosage Strength : 0.02MG/2ML
Approval Date : 2025-02-11
Application Number : 218308
RX/OTC/DISCN : RX
RLD : No
TE Code : AN

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AN
Brand Name : FORMOTEROL FUMARATE
Dosage Form : SOLUTION;INHALATION
Dosage Strength : 0.02MG/2ML
Approval Date : 2022-08-22
Application Number : 215053
RX/OTC/DISCN : RX
RLD : No
TE Code : AN

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AN
Brand Name : FORMOTEROL FUMARATE
Dosage Form : SOLUTION;INHALATION
Dosage Strength : 0.02MG/2ML
Approval Date : 2024-06-26
Application Number : 218304
RX/OTC/DISCN : RX
RLD : No
TE Code : AN

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AN
Brand Name : FORMOTEROL FUMARATE
Dosage Form : SOLUTION;INHALATION
Dosage Strength : 0.02MG/2ML
Approval Date : 2021-06-22
Application Number : 91141
RX/OTC/DISCN : RX
RLD : No
TE Code : AN

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE
Brand Name : BREYNA
Dosage Form : AEROSOL, METERED;INHALATION
Dosage Strength : 0.08MG/INH;0.0045MG/INH
Approval Date : 2022-03-15
Application Number : 211699
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Italy
Brand Name : Fobuler
Dosage Form : Budesonide+Formoterol+4,5160 Mcg 120 Doses Respiratory Use + Easyhaler
Dosage Strength : easyhaler groun inhal 120 doses 160 mcg + 4.5 mcg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Norway
Brand Name : Bufomix Easy Tails
Dosage Form : Inhalasjonspulver
Dosage Strength : 160MCG/Dose; 4.5MCG/Dose
Packaging : Inhalator
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Italy
Brand Name : FOBULER
Dosage Form : Inhalation Powder For Pre-Dosed Inhalation
Dosage Strength : 160 micrograms/4.5 micrograms
Packaging : 120 DOSES (160+4.5) MCG - RESPIRATORY USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Budesonide; Formoterol Fumarate Dihydrate
Brand Name : Bufar Easyhaler
Dosage Form : Inhalation Powder
Dosage Strength : 80mcg/4.5mcg/inhalation
Packaging :
Approval Date : 31/03/2016
Application Number : 20150416000027
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Budesonide; Formoterol Fumarate Dihydrate
Brand Name : Bufori Easyhaler
Dosage Form : Inhalation Powder
Dosage Strength : 80mcg/4.5mcg/inhalation
Packaging :
Approval Date : 02/11/2016
Application Number : 20151205000013
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Budesonide; Formoterol Fumarate Dihydrate
Brand Name : Bufoler Easyhaler
Dosage Form : Inhalation Powder
Dosage Strength : 160mcg/dose;4.5mcg/dose
Packaging :
Approval Date : 22/01/2016
Application Number : 20150207000021
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Budesonide; Formoterol Fumarate Dihydrate
Brand Name : Bufori Easyhaler
Dosage Form : Inhalation Powder
Dosage Strength : 160mcg/dose;4.5mcg/dose
Packaging :
Approval Date : 02/11/2016
Application Number : 20151205000020
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Budesonide; Formoterol Fumarate Dihydrate
Brand Name : Fobumix Easyhaler
Dosage Form : Inhalation Powder
Dosage Strength : 80mcg/4.5mcg/inhalation
Packaging :
Approval Date : 13/01/2017
Application Number : 20160130000029
Regulatory Info : Deregistered
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Budesonide; Formoterol Fumarate Dihydrate
Brand Name : Bufoler Easyhaler
Dosage Form : Inhalation Powder
Dosage Strength : 320mcg/dose;9mcg/dose
Packaging :
Approval Date : 22/01/2016
Application Number : 20150207000038
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Withdrawn
Registration Country : Malta
Budesonide; Formoterol Fumarate Dihydrate
Brand Name : Bufomix Easyhaler Inhalation Powder
Dosage Form : Inhalation Powder
Dosage Strength : 80MCG; 4.5MCG
Packaging :
Approval Date : 2016-07-05
Application Number :
Regulatory Info : Withdrawn
Registration Country : Malta
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
Formoterol fumarate for system suitability
CAS Number : 43229-80-7
Quantity Per Vial : 10 mg
Sale Unit : 1
Order Code : Y0000340
Batch No : 2
Price (€) : 79
Storage : +5°C ± 3°C

Formoterol for impurity I identification
CAS Number : 43229-80-7
Quantity Per Vial : 10 mg
Sale Unit : 1
Order Code : Y0000339
Batch No : 2
Price (€) : 79
Storage : +5°C ± 3°C

CAS Number : 43229-80-7
Quantity Per Vial : 10 mg
Sale Unit : 1
Order Code : F0372000
Batch No : 2
Price (€) : 79
Storage : +5°C ± 3°C

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
25
PharmaCompass offers a list of Formoterol Fumarate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Formoterol Fumarate manufacturer or Formoterol Fumarate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Formoterol Fumarate manufacturer or Formoterol Fumarate supplier.
PharmaCompass also assists you with knowing the Formoterol Fumarate API Price utilized in the formulation of products. Formoterol Fumarate API Price is not always fixed or binding as the Formoterol Fumarate Price is obtained through a variety of data sources. The Formoterol Fumarate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Formoterol Fumarate Dihydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Formoterol Fumarate Dihydrate, including repackagers and relabelers. The FDA regulates Formoterol Fumarate Dihydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Formoterol Fumarate Dihydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Formoterol Fumarate Dihydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Formoterol Fumarate Dihydrate supplier is an individual or a company that provides Formoterol Fumarate Dihydrate active pharmaceutical ingredient (API) or Formoterol Fumarate Dihydrate finished formulations upon request. The Formoterol Fumarate Dihydrate suppliers may include Formoterol Fumarate Dihydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Formoterol Fumarate Dihydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Formoterol Fumarate Dihydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Formoterol Fumarate Dihydrate active pharmaceutical ingredient (API) in detail. Different forms of Formoterol Fumarate Dihydrate DMFs exist exist since differing nations have different regulations, such as Formoterol Fumarate Dihydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Formoterol Fumarate Dihydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Formoterol Fumarate Dihydrate USDMF includes data on Formoterol Fumarate Dihydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Formoterol Fumarate Dihydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Formoterol Fumarate Dihydrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Formoterol Fumarate Dihydrate Drug Master File in Japan (Formoterol Fumarate Dihydrate JDMF) empowers Formoterol Fumarate Dihydrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Formoterol Fumarate Dihydrate JDMF during the approval evaluation for pharmaceutical products. At the time of Formoterol Fumarate Dihydrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Formoterol Fumarate Dihydrate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Formoterol Fumarate Dihydrate Drug Master File in Korea (Formoterol Fumarate Dihydrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Formoterol Fumarate Dihydrate. The MFDS reviews the Formoterol Fumarate Dihydrate KDMF as part of the drug registration process and uses the information provided in the Formoterol Fumarate Dihydrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Formoterol Fumarate Dihydrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Formoterol Fumarate Dihydrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Formoterol Fumarate Dihydrate suppliers with KDMF on PharmaCompass.
A Formoterol Fumarate Dihydrate CEP of the European Pharmacopoeia monograph is often referred to as a Formoterol Fumarate Dihydrate Certificate of Suitability (COS). The purpose of a Formoterol Fumarate Dihydrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Formoterol Fumarate Dihydrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Formoterol Fumarate Dihydrate to their clients by showing that a Formoterol Fumarate Dihydrate CEP has been issued for it. The manufacturer submits a Formoterol Fumarate Dihydrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Formoterol Fumarate Dihydrate CEP holder for the record. Additionally, the data presented in the Formoterol Fumarate Dihydrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Formoterol Fumarate Dihydrate DMF.
A Formoterol Fumarate Dihydrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Formoterol Fumarate Dihydrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Formoterol Fumarate Dihydrate suppliers with CEP (COS) on PharmaCompass.
A Formoterol Fumarate Dihydrate written confirmation (Formoterol Fumarate Dihydrate WC) is an official document issued by a regulatory agency to a Formoterol Fumarate Dihydrate manufacturer, verifying that the manufacturing facility of a Formoterol Fumarate Dihydrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Formoterol Fumarate Dihydrate APIs or Formoterol Fumarate Dihydrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Formoterol Fumarate Dihydrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Formoterol Fumarate Dihydrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Formoterol Fumarate Dihydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Formoterol Fumarate Dihydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Formoterol Fumarate Dihydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Formoterol Fumarate Dihydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Formoterol Fumarate Dihydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Formoterol Fumarate Dihydrate suppliers with NDC on PharmaCompass.
Formoterol Fumarate Dihydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Formoterol Fumarate Dihydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Formoterol Fumarate Dihydrate GMP manufacturer or Formoterol Fumarate Dihydrate GMP API supplier for your needs.
A Formoterol Fumarate Dihydrate CoA (Certificate of Analysis) is a formal document that attests to Formoterol Fumarate Dihydrate's compliance with Formoterol Fumarate Dihydrate specifications and serves as a tool for batch-level quality control.
Formoterol Fumarate Dihydrate CoA mostly includes findings from lab analyses of a specific batch. For each Formoterol Fumarate Dihydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Formoterol Fumarate Dihydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Formoterol Fumarate Dihydrate EP), Formoterol Fumarate Dihydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Formoterol Fumarate Dihydrate USP).